Xconomy: Omeros Plans to Test Waters with First Washington IPO in Two Years, Sources Say
Summary
Omeros Plans to Test Waters with First Washington IPO in Two Years, Sources Say (Page 2 of 2) clinical trial with 1,040 patients.If ongoing trials are successful, Omeros plans to ask the FDA for approval to start marketing the drug in the second half of 2010, according to the most recent regulatory filing.Omeros lists two other drugs in its pipeline for reducing the complications of surgery—one for eye surgeries, and another for urinary tract procedures.Besides getting more capital to fuel its drug development pipeline, an IPO would provide all-important liquidity to a broad network of angel and venture investors who have stuck with the company for years.If successful, Omeros hopes to be listed under the ticker symbol “OMER.” The offering would be underwritten by Deutsche Bank Securities, Wedbush Pacific Growth Life Sciences, Leerink Swann, and Needham & Company, according to the filing.